Aclaris Therapeutics, Inc. (ACRS) intrinsic value & 10-year financials
Aclaris Therapeutics, Inc. (ACRS) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 21.2% a year to $7.8M, with an average return on invested capital of -80.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.28
- Market cap
- $402.0M
- Revenue (FY2025)
- $7.8M
- Revenue growth (10-yr CAGR)
- 21.2%
- ROIC (10-yr avg)
- -80.3%
- Free cash flow (FY2025)
- -$47.2M
ACRS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.8M | -$64.9M | -$0.53 | -$47.2M | -975.9% | -59.6% |
| FY2024 | $18.7M | -$132.1M | -$1.71 | -$20.2M | -758.2% | -104.2% |
| FY2023 | $31.2M | -$88.5M | -$1.27 | -$79.6M | -311.6% | -70.7% |
| FY2022 | $29.8M | -$86.9M | -$1.33 | -$68.2M | -302.0% | -53.3% |
| FY2021 | $6.8M | -$90.9M | -$1.60 | -$52.4M | -1327.1% | -90.3% |
| FY2020 | $6.5M | -$51.0M | -$1.20 | -$39.1M | -785.4% | -148.3% |
| FY2019 | $4.2M | -$161.4M | -$3.90 | -$98.1M | -2627.3% | -142.0% |
| FY2018 | $10.1M | -$132.7M | — | -$102.2M | -1341.9% | -70.6% |
| FY2017 | $1.7M | -$68.5M | — | -$55.9M | -4303.2% | -35.7% |
| FY2016 | — | -$48.1M | — | -$34.8M | — | -28.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Aclaris Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Aclaris Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -92.4% ROIC.
Aclaris Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Aclaris Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-17.60 per share.